Published research on Ivermectin
5 peer-reviewed publications on Ivermectin in oncology research, clinical work first, then laboratory studies. Each entry reports what the authors stated; follow the link for the full paper.
- Review
Ivermectin, a potential anticancer drug derived from an antiparasitic drug
The authors reviewed reported mechanisms by which ivermectin inhibited proliferation and promoted programmed cell death in various cancer cells and discussed prospects for its clinical application in oncology.
- Review
The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug
The authors summarised in vitro and in vivo evidence that ivermectin exerted antitumour effects in several cancer types via multiple targets, at concentrations they considered clinically reachable based on human pharmacokinetic data.
- In vivo
Ivermectin Induces Cytostatic Autophagy by Blocking the PAK1/Akt Axis in Breast Cancer
Ivermectin induced cytostatic autophagy in breast cancer cells through degradation of PAK1 and blockade of Akt/mTOR signalling, and suppressed tumour growth in breast cancer xenografts.
- In vivo
Ivermectin inhibited growth and induced caspase-dependent apoptosis in U87 and T98G glioblastoma cells, suppressed growth of two glioblastoma xenograft models, and inhibited angiogenesis via mitochondrial dysfunction and oxidative stress.
- In vivo
Ivermectin induced cell death at low micromolar concentrations in acute myeloid leukemia cell lines and primary patient samples preferentially over normal hematopoietic cells, and delayed tumour growth in three mouse models of leukemia.
Ivermectin in the catalog (specifications, pack sizes, Certificate of Analysis)